Allergy immunotherapy | ALK
Healthcare professionals

Allergy immunotherapy

Targets the root cause of allergy by stimulating an immune response

Allergy immunotherapy (AIT) is the only treatment of allergic disease that addresses the underlying cause of the disease: the immune system. Therefore, it is also the only treatment capable of modifying the course of the disease.

It works by administering repeated doses of the specific allergen that the patient is allergic to. This stimulates an immune response in the body, which causes the patient to build up immunological tolerance against the given allergen. 

AIT is proven not only to improve the patient’s symptoms and need for symptom-relieving medication, but also to induce specific tolerance beyond the duration of the treatment. By targeting the specific allergen that triggers a patient’s symptoms, AIT inhibits the occurrence of both seasonal and perennial allergic reactions. 

Disease-modifying and protective effect

To achieve long-term sustained effect, where the benefits of the treatment continue after the treatment has ended, it is recommended to treat with AIT for three to five years. Because of the induced immunological tolerance, AIT not only provides long-term relief of symptoms and improvement of quality of life, but also has the potential of preventing onset of new sensitisations, allergic conditions, and progression into asthma as well as impacting asthma severity. Neither of these disease-modifying and protective effects are possible with symptom-relieving medication. 

Why has AIT disease-modifying effect?

References
  • Alvaro-Lozano M et al. EAACI Allergen Immunotherapy User's Guide. Pediatr Allergy Immunol. 2020;31 Suppl 25(Suppl 25):1-101
  • Durham SR et al. J Allergy Clin Immunol. 2012;129(5):717-725; 2
  • Global Atlas of Allergy, EAACI 2014
  • Larsen JN et al. Drug Discov Today 2016:21(1):26-37
  • Penagos M, Durham S. Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. Allergy Asthma Proc 202243(4):292-298
  • Shamji MH et al. J Allergy Clin Immunol 2017;140(6):1485-1498
  • Valovirta E et al. J Allergy Clin Immunol. 2018;141(2):529-38
Last updated: 05.07.2019